SCHEMBL2815922

SCHEMBL2815922

Cc1ccc(C(=O)Nc2ccc(-c3cc(C(C)(C)C)nc4[nH]nc(N)c34)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.49
KIT P10721 7/20 0.49
FLT3 P36888 6/20 0.49
ABL1 P00519 4/20 0.47
BCR P11274 2/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CSF1R P07333 4/20 0.44
FLT1 P17948 4/20 0.44
FLT4 P35916 4/20 0.44
AURKA O14965 3/20 0.44
AURKB Q96GD4 3/20 0.44
CDK19 Q9BWU1 3/20 0.44
LCK P06239 3/20 0.44
PLK4 O00444 2/20 0.44
DYRK3 O43781 2/20 0.44
ROCK2 O75116 2/20 0.44
RPS6KA5 O75582 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2817289 0.91 KDR (0.60) KDRKITFLT3ABL1CSF1R
SCHEMBL2816521 0.90 KIT (0.51) KDRKITFLT3ABL1BCR
SCHEMBL2816792 0.86 KDR (0.58) KDRKITFLT3ABL1CSF1R
SCHEMBL2228840 0.86 KDR (0.42) KDRKITFLT3ABL1BCR
SCHEMBL14367013 0.84 KDR (0.52) KDRKITFLT3ABL1CSF1R
SCHEMBL2816061 0.84 TP53 (0.53) KITFLT3ABL1BCRNPC1
SCHEMBL2821053 0.84 LTK (0.46) KDRKITFLT3ABL1BCR
SCHEMBL2819284 0.83 KDR (0.58) KDRKITFLT3ABL1CSF1R
SCHEMBL2816084 0.83 KDR (0.66) KDRKITFLT3ABL1CSF1R
SCHEMBL2816524 0.83 KDR (0.53) KDRKITFLT3ABL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842809-B2 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same BAYER SCHERING PHARMA AG (DE) 2010-11-30 US claimed
EP-1841767-A1 PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE Bayer Schering Pharma AG (DE) 2007-10-10 EP claimed
US-20060252754-A1 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same BAYER INTELLECTUAL PROPERTY GMBH (DE) 2006-11-09 US claimed
WO-2006077168-A1 PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE BAYER SCHERING PHARMA AG. (DE) 2006-07-27 WO claimed
US-7842809-B2 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same BAYER SCHERING PHARMA AG (DE) 2010-11-30 US disclosed
US-7842809-B2 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same BAYER SCHERING PHARMA AG (DE) 2010-11-30 US disclosed
US-7842809-B2 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same BAYER SCHERING PHARMA AG (DE) 2010-11-30 US disclosed
EP-1841767-A1 PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE Bayer Schering Pharma AG (DE) 2007-10-10 EP disclosed
US-20060252754-A1 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same BAYER INTELLECTUAL PROPERTY GMBH (DE) 2006-11-09 US disclosed
WO-2006077168-A1 PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE BAYER SCHERING PHARMA AG. (DE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252754-A1 Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same TEK, TIE1, KDR KDR 3/4885KIT 8/4885FLT3 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.